Brown bear (Ursus arctos)

DamianKuzdak

We previously covered Pfizer (NYSE:NYSE:PFE) in September 2023, discussing its pessimistic performance as the decelerating COVID-19 portfolio and underperforming bolt-on acquisitions had contributed to its lowered FY2023 guidance range.

Combined with the overly aggressive R&D efforts, expensive acquisitions, and deteriorating balance sheet, we

Source link